Sees FY23 revenue growth 8%-10%, or approximately $118M-$121M in net revenues and Adjusted EBITDA to be greater than $22M. Sees FY23 Adjusted EBITDA margin to be greater than 19% for the year. CEO Richard DiIorio, said, "Looking forward, we are estimating full-year 2023 revenue growth to be in the range of 8% to 10% with Adjusted EBITDA margin to be greater than 19% for the year. As we enter 2023, our financial strength, combined with our talented and dedicated team, gives me confidence in our ability to advance our vision to improve patient care, by providing unique solutions that promote healing, facilitating clinic-to-home, lowering the cost of care and enhancing patient outcomes which will enable us to deliver robust growth for years to come."
Published first on TheFly